Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Equity Income: 2019-2024

Historic Equity Income for Ultragenyx Pharmaceutical (RARE) over the last 6 years, with Dec 2024 value amounting to -$1.1 million.

  • Ultragenyx Pharmaceutical's Equity Income changed negligibly% to $678,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.0 million, marking a year-over-year decrease of 144.62%. This contributed to the annual value of -$1.1 million for FY2024, which is 380.86% down from last year.
  • Latest data reveals that Ultragenyx Pharmaceutical reported Equity Income of -$1.1 million as of FY2024, which was down 380.86% from $397,000 recorded in FY2023.
  • In the past 5 years, Ultragenyx Pharmaceutical's Equity Income ranged from a high of $170.4 million in FY2020 and a low of -$42.1 million during FY2021.
  • In the last 3 years, Ultragenyx Pharmaceutical's Equity Income had a median value of -$1.1 million in 2024 and averaged -$6.7 million.
  • In the last 5 years, Ultragenyx Pharmaceutical's Equity Income soared by 1,170.43% in 2020 and then slumped by 380.86% in 2024.
  • Yearly analysis of 5 years shows Ultragenyx Pharmaceutical's Equity Income stood at $170.4 million in 2020, then slumped by 124.68% to -$42.1 million in 2021, then spiked by 54.12% to -$19.3 million in 2022, then surged by 102.06% to $397,000 in 2023, then crashed by 380.86% to -$1.1 million in 2024.